Extended treatment of childhood Charcot-Marie-Tooth disease with high-dose ascorbic acid

Journal of the Peripheral Nervous System

Volumn 16, Issue 3, 2011, Pages 272-274

  Burns, Joshua ^a   Ouvrier, Robert A ^a   Yiu, Eppie M ^b,c   Ryan, Monique M ^b,c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID;

ADOLESCENT; CHILD; CHILDHOOD; CLINICAL ARTICLE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LETTER; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE STRENGTH; NEUROLOGIC EXAMINATION; NEUROPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ASCORBIC ACID; CHARCOT-MARIE-TOOTH DISEASE; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; VITAMINS;

EID: 80055025449     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00348.x     Document Type: Letter

References (15)

1. Burns J, Bray P, Cross L, North KN, Ryan MM, Ouvrier RA, (2008). Hand involvement in children with Charcot-Marie-Tooth disease type 1A. Neuromuscul Disord 18: 970-973.
2. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM, (2009a). Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 8: 537-544.
3. Burns J, Ryan MM, Ouvrier RA, (2009b). Evolution of foot and ankle manifestations in children with CMT1A. Muscle Nerve 39: 158-166.
4. Burns J, Ramchandren S, Ryan MM, Shy M, Ouvrier RA, (2010). Determinants of reduced health-related quality of life in pediatric inherited neuropathies. Neurology 75: 726-731.
5. LeGuern E, Gouider R, Mabin D, Tardieu S, Birouk N, Parent P, Bouche P, Brice A, (1997). Patients homozygous for the 17p11.2 duplication in Charcot-Marie-Tooth type 1A disease. Ann Neurol 41: 104-108. (Pubitemid 27057099)
6. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, Saucedo-Cardenas O, Barker DF, Killian JM, Garcia CA, Chakravarti A, Patel PI, (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66: 219-232. (Pubitemid 121001361)
7. Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, Bernard R, Jouve E, Pitel S, Vacherot F, Remec JF, Jomir L, Azabou E, Al-Moussawi M, Lefebvre MN, Attolini L, Yaici S, Tanesse D, Fontes M, Pouget J, Blin O, (2009). Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 8: 1103-1110.
8. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laurà M, Radice D, Calabrese D, Hughes RAC, Solari A, (2011). Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol 10: 320-328.
9. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M, (2004). Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10: 396-401. (Pubitemid 38508518)
10. Sturtz F, Latour P, Mocquard Y, Cruz S, Fenoll B, LeFur JM, Mabin D, Chazot G, Vandenberghe A, (1997). Clinical and electrophysiological phenotype of a homozygously duplicated Charcot-Marie-Tooth (Type 1A) disease. Eur Neurol 38: 26-30. (Pubitemid 27283075)
11. Verhamme C, de Haan R, Vermeulen M, Baas F, de Visser M, van Schaik I, (2009). Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial. BMC Medicine 7: 70.
12. Weterman MA, van Ruissen F, de Wissel M, Bordewijk L, Samijn JP, van der Pol WL, Meggouh F, Baas F, (2010). Copy number variation upstream of PMP22 in Charcot-Marie-Tooth disease. Eur J Hum Genet 18: 421-428.
13. Yiu E, Burns J, Ryan MM, Ouvrier RA, (2008). Neurophysiologic abnormalities in children with Charcot-Marie-Tooth disease type 1A. J Peripher Nerv Syst 13: 236-241.
14. Zhang F, Khajavi M, Connolly AM, Towne CF, Batish SD, Lupski JR, (2009). The DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex rearrangements in humans. Nat Genet 41: 849-853.
15. Zhang F, Seeman P, Liu P, Weterman MA, Gonzaga-Jauregui C, Towne CF, Batish SD, De Vriendt E, De Jonghe P, Rautenstrauss B, Krause KH, Khajavi M, Posadka J, Vandenberghe A, Palau F, Van Maldergem L, Baas F, Timmerman V, Lupski JR, (2010). Mechanisms for nonrecurrent genomic rearrangements associated with CMT1A or HNPP: rare CNVs as a cause for missing heritability. Am J Hum Genet 86: 892-903.